Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
46 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Pharmaxis Limited - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Pharmaxis Limited - Product Pipeline Review - 2014', provides an overview of the Pharmaxis Limited's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Pharmaxis Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Pharmaxis Limited including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Pharmaxis Limited's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Pharmaxis Limited's pipeline products Reasons to buy - Evaluate Pharmaxis Limited's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Pharmaxis Limited in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Pharmaxis Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Pharmaxis Limited and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pharmaxis Limited - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Pharmaxis Limited and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Pharmaxis Limited Snapshot 5 Pharmaxis Limited Overview 5 Key Information 5 Key Facts 5 Pharmaxis Limited - Research and Development Overview 6 Key Therapeutic Areas 6 Pharmaxis Limited - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pharmaxis Limited - Pipeline Products Glance 11 Pharmaxis Limited - Late Stage Pipeline Products 11 Filing rejected/Withdrawn Products/Combination Treatment Modalities 11 Pharmaxis Limited - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 Pharmaxis Limited - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Discovery Products/Combination Treatment Modalities 15 Pharmaxis Limited - Drug Profiles 16 mannitol 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 ASM-8 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 PXS-25 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 PXS-64 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 PXS-2200 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 PXS-4159 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 PXS-4206 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 PXS-4681A 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 PXS-4728A 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 PXSTPI-1100 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Small Molecules to Inhibit LOXL2 for Oncology and Fibrosis 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 PXS-4820 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 PXS-5033-A 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Pharmaxis Limited - Pipeline Analysis 32 Pharmaxis Limited - Pipeline Products by Target 32 Pharmaxis Limited - Pipeline Products by Route of Administration 34 Pharmaxis Limited - Pipeline Products by Molecule Type 35 Pharmaxis Limited - Pipeline Products by Mechanism of Action 36 Pharmaxis Limited - Recent Pipeline Updates 38 Pharmaxis Limited - Dormant Projects 43 Pharmaxis Limited - Locations And Subsidiaries 44 Head Office 44 Other Locations & Subsidiaries 44 Appendix 45 Methodology 45 Coverage 45 Secondary Research 45 Primary Research 45 Expert Panel Validation 45 Contact Us 46 Disclaimer 46
List of Tables Pharmaxis Limited, Key Information 5 Pharmaxis Limited, Key Facts 5 Pharmaxis Limited - Pipeline by Indication, 2014 8 Pharmaxis Limited - Pipeline by Stage of Development, 2014 9 Pharmaxis Limited - Monotherapy Products in Pipeline, 2014 10 Pharmaxis Limited - Filing rejected/Withdrawn, 2014 11 Pharmaxis Limited - Phase II, 2014 12 Pharmaxis Limited - Phase I, 2014 13 Pharmaxis Limited - Preclinical, 2014 14 Pharmaxis Limited - Discovery, 2014 15 Pharmaxis Limited - Pipeline by Target, 2014 33 Pharmaxis Limited - Pipeline by Route of Administration, 2014 34 Pharmaxis Limited - Pipeline by Molecule Type, 2014 35 Pharmaxis Limited - Pipeline Products by Mechanism of Action, 2014 37 Pharmaxis Limited - Recent Pipeline Updates, 2014 38 Pharmaxis Limited - Dormant Developmental Projects,2014 43 Pharmaxis Limited, Subsidiaries 44
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.